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A B S T R A C T
The purpose of this study was to investigate the validation of the translated and culturally adapted CDQ-24 question-
naire on a group of Serbian patients. The study was comprised of 100 consecutive patients with idiopathic cervical
dystonia (CD) and blepharospasm (BSP) who were evaluated at the Institute of Neurology, Clinical Centre of Serbia in
Belgrade between March and June 2007. The linguistic validation of CDQ-24 involved 3 steps, according to an interna-
tionally accepted methodology. Most of the patients with CD and BSP accepted the CDQ-24 questionnaire. The internal
consistency reliability ranged from 0.81 to 0.97. The mean total score of the CDQ-24 was 35.6±23.5. Patients with BSP
had better HRQoL scores in the Pain subscale (p=0.025) compared with CD patients. However, patients with CD had
better HRQoL sores in the Activities of Daily Living subscale (p=0.028) compared with BSP patients. Statistically signif-
icant positive correlations were registered between the Dystonia Movement Scale score and almost all CDQ-24 scales.
The Serbian version of CDQ-24 should be recommended for HRQoL evaluation among patients with CD and BSP as an
important outcome measure.
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Introduction
Dystonia is involuntary movement characterized by
sustained muscle contractions usually producing twist-
ing and repetitive movements or abnormal postures1. In
a cross-sectional study of primary dystonia in 8 Euro-
pean countries, the prevalence was 15.2/100 000 with fo-
cal dystonia having the highest value of 11.7/100 0002.
According to the Serbian epidemiologic study the preva-
lence of late onset focal dystonia in Belgrade (capital of
Serbia) was 15.4/100 0003.
All types of primary dystonia are frequently associated
with depression and social disabilities, emphasizing its im-
pact on the impairment of health-related quality of life
(HR-QoL)4. Although the SF-36 is the most widely used ge-
neric measure of health status and has been already used
in dystonia4–6, there is a need for development of the dis-
ease-specific instruments for measuring specific problems
in patients with different types of dystonia, particularly for
assessment of their functional health and treatment ef-
fects7. The Craniocervical Dystonia Questionnaire (CDQ-
-24) was developed at Innsbruck University (Austria) as a
disease-specific instrument to measure the quality of life of
patients with craniocervical dystonia7.
A large number of patients with different types of
dystonia from all parts of Serbia are treated and followed
at both inpatient and outpatients settings of the Depart-
ment of Movement Disorders, the Institute of Neurology,
Clinical Center of Serbia, in Belgrade, which is a primary
referral national center for diagnosis and treatment of
these disorders in Serbia. Thus, we had opportunity for
studing the wide range of problems related to different
aspects of dystonia8–12. However, keeping in mind all lim-
itations of HR-QoL generic measures, as well as the large
number of our patients, we decided to make possible us-
age of CDQ-24, the first patient-based rating scale both
for cranial and cervical dystonia.
The objective of this study was to determine the vali-
dation of the translated and culturally adapted CDQ-24
questionnaire on a group of 100 Serbian patients.
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Patients and Methods
The study was comprised of 100 consecutive patients
with idiopathic cervical dystonia (CD) and blepharo-
spasm (BSP) who presented for botulinum toxin type A
treatment in the outpatient setting of the Movement Dis-
orders Department, the Institute of Neurology, Clinical
Centre of Serbia, Belgrade, between March and June,
2007. We did not include patients with neurologic abnor-
malities in addition to dystonia, a robust response to
levodopa (dopa-responsive dystonia), a history of exposure
to dopamine receptor blocking agents within 6 months be-
fore the onset of dystonia, severe head trauma with a loss
of consciousness, and features suggesting various types
of secondary dystonia. The standard supplementary in-
vestigations included magnetic resonance imaging (MRI)
and/or computed tomography (CT) of the brain and cer-
vical region, electroencephalography, extensive labora-
tory analyses (including serum levels of ceruloplasmin,
urine copper levels, thyroid function tests, and a blood
smear for accanthocytosis).
The study was approved by the Ethical Committee of
the Clinical Center of Serbia. All participants were in-
cluded after giving the informed consent.
In this study, HRQoL was measured by the disease-
-specific instrument, CDQ-24 which includes 24 questions
divided in 5 domains: Stigma (9 items), Emotional Well-
being (5 items), Pain (3 items), Activities of Daily Living (7
items), and Social/Family Life (4 items). Each item con-
sists of 5 statements representing increasing severity of
impairment, scored from 0 to 4. In order to obtain compa-
rable scores for individual subscales, the raw subscores
(sum of the individual item scores) were linearly trans-
formed to a 0–100 scale, where a score of 0 indicates the
best and a score of 100 the worst possible quality of life7.
We performed translation and cultural adaptation of
the original version of the CDQ-247, with the aim to pro-
duce a translated version in Serbian which is conceptu-
ally equivalent to the original version, as well as being
clear and easy to understand. The linguistic validation
involved three steps: a) translation of the original CDQ-
-24 into Serbian (forward translation); b) the questions
of the first Serbian version of CDQ-24 were translated
back into English (backward translation) and c) patient
testing. Two professional translators, with the assistance
of quality of life experts and clinicians performed both
forward and backward translations. They discussed con-
troversial items to produce a final version of the CDQ-24
which would be most appropriate for the cultural milieu
of Serbia and acceptable for testing on patients with CD
and BSP. In the 3rd step, we performed patient testing
with the aim to test the translated questionnaire on pa-
tients to determine whether it was acceptable, whether it
was understood in the way it was supposed to, and
whether the language used was simple and appropriate.
In order to verify acceptability and interpretation of the
translated items, the questionnaire was tested on 5 pa-
tients, 3 with CD and 2 with BSP. In this phase the
CDQ-24 was performed through face-to-face interviews
during which the physician-investigator inquired whether
the patient had any difficulty in understanding the ques-
tionnaire and checked the patient’s interpretation of all
items. The results of these tests were discussed in the
same group of experts, which led to the final Serbian ver-
sion of the CDQ-24.
The CDQ-24 was filled in by patients in the presence
of a physician who assisted the patient, if necessary. A
neurologist collected the main clinical data and assessed
disability using the Tsui score13 for CD, the Blepharo-
spasm Rating Scale14 for BSP and the Dystonia Move-
ment Scale15 for both.
The internal reliabilities of CDQ-24 (Serbian version)
were assessed by Cronbach’s alpha coefficient, with a
range from 0–1, the latter indicating perfect reliability.
Clinical validity was quantified by the comparison of
CDQ-24 subscales scores and the values of the Score for
Spasmodic Torticollis13 for CD, the Blepharospasm Rating
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TABLE 1
DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PA-



























































Disease durationa (years) 8.4±6.4 (1–24) 7.6±7.0 (1–30)
Severity of dystonia a
Dystonia Movement Scale








De novo patientsb 11 (18.3%) 4 (10.0%)
a X±SD (range), b No previous botulinum toxin treatment
Scale14 for BSP, and the Dystonia Movement Scale15 for
both. Pearson’s correlation coefficient (r) was used to in-
vestigate the relationship between the scores mentioned
above and the main clinical and demographic variables.
Results
One hundred consecutive patients with CD (60) and
BSP (40) were included in CDQ-24 (Serbian version) vali-
dation. Selected demographic and clinical characteristics
of our patients with CD and BSP are presented in Table 1.
Most of the patients with CD and BSP accepted the
CDQ-24 questionnaire well. The majority of the patients
(97%) estimated the questions as clear and understand-
able. None of the items were interpreted as unpleasant
and embarrassing. The mean time to complete the ques-
tionnaire was 11 minutes (range, 4–21 minutes).
Descriptive statistics of the CDQ-24 subscales are
shown in Table 2, both for the total sample, and for CD
and BSP separately. The mean total score of the CDQ-24
was 35.6±23.5 (range 1.7–96.7). Patients with BSP had a
better HRQoL score (lower score) in the Pain subscale
(p=0.025) compared with the CD patients. However, pa-
tients with CD had a better HRQoL score (lower score) in
the Activities of Daily Living subscale (p=0.028) com-
pared with patients with BSP.
Internal consistency reliability ranged from 0.81 on
the Activities of Daily Living subscale to 0.97 on the
Stigma, the Emotional Wellbeing and the Overall Quality
of Life subscales (Table 3).
There was a weak statistically non-significant corre-
lation between the scores of the CDQ-24 subscales and
the Score for Spasmodic Torticollis, except for the Activ-
ities of Daily Living subscale (r=0.381, p<0.01). A statis-
tically significant positive correlation was also found for
the Overall Quality of Life score and the Score for Spas-
modic Torticollis (r=0.255, p<0.05) (Table 4).
In BSP patients, a statistically significant positive
correlation was found between the Blepharospasm Rat-
ing Scale and all of the CDQ-24 subscales, except for the
Pain subscale (Table 5).
According to the findings shown in Table 6, a statisti-
cally significant positive correlation was registered be-
tween the Dystonia Movement Scale score and all CDQ-
-24 scales, except for the Emotional Wellbeing subscale in
CD patients, and the Pain subscale in BSP patients.
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TABLE 2
DESCRIPTIVE STATISTICS FOR THE CDQ-24 (SERBIAN VERSION)







Stigma 40.2±29.3 37.8±32.9 0.707 39.3±30.7
Emotional well-being 37.8±29.6 37.5±32.1 0.958 37.7±30.5
Pain 30.1±24.7 18.9±22.9 0.025 25.6±24.5
Activities of daily living 38.9±20.7 49.3±25.3 0.028 43.1±23.1
Social/family life 32.1±24.9 32.2±28.6 0.995 32.1±26.3
Total score 35.8±22.3 35.1±25.5 0.884 35.6±23.5
TABLE 3












Stigma 6 0.97 0.89
Emotional well-being 5 0.97 0.88
Pain 3 0.84 0.79
Activities of daily living 6 0.81 0.77
Social/family life 4 0.90 0.85
Total score 24 0.97 0.94
TABLE 4
CLINICAL VALIDITY: CORRELATION OF CDQ-24
(SERBIAN VERSION) WITH SCORE FOR SPASMODIC
TORTICOLLIS IN PATIENTS WITH CERVICAL DYSTONIA









CLINICAL VALIDITY: CORRELATION OF CDQ-24
(SERBIAN VERSION) WITH BLEPHAROSPASM RATING
SCALE IN PATIENTS WITH BLEPHAROSPASM









The Medical Outcome Study 36-item Short Form Health
Survey (SF-36) is the most widely used generic measure
of health status and has been already used in dystonia5,6.
A recent study revealed that HRQoL in CD patients is
mainly predicted by factors such as self-esteem, self-dep-
recation, social participation, social support, stigma, anx-
iety and depression, all of which are not addressed by a
generic HRQoL instrument4,7,16.
The CDQ-24 was created as a disease-specific quality
of life instrument that addressed the special perceptions
and concerns of CD and BSP patients, and can be used to
evaluate the impact of the disease on areas not covered
by generic measures7. The CDQ-24 has revealed good re-
liability properties according to generally accepted crite-
ria in quality of life assessment17. It does mean that the
scales of CDQ-24 are appropriately measured.
In our study, the mean total CDQ-24 score was 35.6±
23.5, which is identical to the one obtained in the original
study7. In both studies, BSP patients scored statistically
significantly better HRQoL in the Pain subscale com-
pared with CD patients. We found that CD patients
showed a statistically significantly better HRQoL score
in the Activities of Daily Living subscale, compared to
BSP patients. The differences are also observed in the
Social/family life subscale, i.e., Austrian patients with
both CD and BSP scored better in this domain compared
to Serbian patients, implicating a lack of psychological
support and social functioning of our patients.
In this investigation, statistically significant positive
correlations were registered between the Dystonia Move-
ment Scale score and all CDQ-24 scales, except for the
Emotional Wellbeing subscale in patients with CD, and
the Pain subscale in patients with BSP, implicating ac-
ceptable clinical validity. Similarly to the original study7,
CDQ-24 subscores showed a weak correlation with the
Score for Spasmodic Torticollis in CD patients. We did
not find a reasonable explanation for absence of these
correlations in the extant literature. In agreement with
these findings, it has been taken into consideration that
the Score for Spasmodic Torticollis is based on objective
neurologic examination, while the quality of life scores
represent subjective patients’ perception. In other words,
some patients with severe CD might ignore their difficul-
ties caused by the disease and show better scores in the
quality of life assessment.
In conclusion, the Serbian version of CDQ-24 should
be recommended for HRQoL evaluation among patients
with both CD and BSP, as an important outcome measure.
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TABLE 6
CLINICAL VALIDITY: CORRELATION OF CDQ-24










Emotional well-being 0.219 0.483**
Pain 0.394** 0.22
Activities of daily living 0.445** 0.520**
Social/family life 0.400** 0.541**
Total score 0.393** 0.510**
*p<0.05, **p<0.01
UPITNIK KRANIOCERVIKALNE DISTONIJE (CDQ-24): VALJANOST I KULTURALNA PRILAGODBA
ZA SRPSKE PACIJENTE
S A @ E T A K
Cilj ove studije je istra`iti valjanost prevedenog i kulturalno prilago|enog upitnika kraniocervikalne distonije (CDQ-24)
na grupi srpskih pacijenata. Studija je sadr`avala 100 pacijenata s idiopatskom cervikalnom distonijom (CD) i ble-
farospazmom (BSP) koji su bili ispitani na Institutu za neurologiju, Sveu~ili{nog klini~kog centra Srbije u Beogradu, u
periodu od o`ujka do lipnja 2007. godine. Lingvisti~ka valjanost CDQ-24 uklju~ivala je 3 koraka, prema me|unarodno
prihva}enoj metodologiji. Ve}ina pacijenata s CD i BSP prihvatila je upitnik. Interna dosljednost pouzdanosti rangirala
je od 0,81 do 0,97. Aritmeti~ka sredina sveukupnog rezultata je 35,6±23,5. Pacijenti s BSP imali su bolje rezultate
kvalitete `ivota povezane sa zdravljem (HRQoL) na podskali boli (p=0,025) u odnosu na pacijente sa CD. Me|utim,
pacijenti sa CD imali su bolje HRQoL rezultate na podskali aktivnosti svakodnevnog `ivota (p=0,028) u odnosu na
pacijente s BSP. Statisti~ki zan~ajna pozitivna korelacija registrirana je izme|u rezultata skale distonijskog micanja i
gotovo svih CDQ-24 rezultata. Srpska ina~ica CDQ-24 trebala bi biti preporu~ena za evaluaciju HRQoL me|u pacijen-
tima sa CD i BSP kao va`na ishodi{na mjera.
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